Oncological Outcomes of Patients with Ductal Adenocarcinoma of the Prostate Receiving Radical Prostatectomy or Radiotherapy

Overview

Journal Asian J Urol

Specialty Urology

Date 2021 May 17

PMID 33996481

Citations 1

Authors

Mengzhu Liu

Kun Jin

Shi Qiu

Pengyong Xu

Mingming Zhang

Wufeng Cai

Xiaonan Zheng

Lu Yang

Qiang Wei

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the oncological outcomes of ductal adenocarcinoma of the prostate (DAC) managed with radical prostatectomy (RP) or radiotherapy (RT) and optimize the proper treatment modality to DAC comprehensively.

Methods: The cohorts included a total of 528 patients from the Surveillance, Epidemiology and End Results (SEER) database, 354 receiving RP and 174 receiving RT. Cox proportional hazards regressions were performed to assess cancer specific mortality (CSM) and overall mortality (OM) between treatment groups. A competing risk analysis was further conducted. Subgroup analyses by age and level of prostate-specific antigen (PSA) were performed. Propensity score matching was implemented.

Results: Patients managed with RP had lower risks of CSM and OM compared with RT (before matching: Hazard ratio [HR]=0.24, 95% confidence interval [CI] 0.13-0.47 and HR=0.26, 95% CI 0.17-0.40, respectively; after matching: HR=0.18, 95% CI 0.04-0.82 and HR=0.28, 95% CI 0.11-0.70, accordingly). Subgroup analyses demonstrated that patients in the middle tertile of the age or with lower tertile PSA level managed with RP took lower risks of OM significantly (HR=0.18, 95% CI 0.06-0.57, <0.01 and HR=0.17, 95% CI 0.06-0.54, <0.01).

Conclusion: Among patients with DAC, treatment with RP was associated with better survival outcomes in comparison with RT. Patients with DAC in the middle tertile of the age and with lower tertile PSA level benefited the most from RP.

Citing Articles

Are we progressing in prostate cancer management?.

Patel H, Patel R Asian J Urol. 2021; 8(2):241-242.

PMID: 33996484 PMC: 8099682. DOI: 10.1016/j.ajur.2020.09.001.

References

Seipel A, Delahunt B, Samaratunga H, Amin M, Barton J, Berney D . Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists. Histopathology. 2014; 65(2):216-27. DOI: 10.1111/his.12382. View

Gillard M, Lack J, Pontier A, Gandla D, Hatcher D, Sowalsky A . Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer. Eur Urol Focus. 2017; 5(3):433-442. PMC: 6614018. DOI: 10.1016/j.euf.2017.12.003. View

Meeks J, Zhao L, Cashy J, Kundu S . Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program. BJU Int. 2011; 109(6):831-4. DOI: 10.1111/j.1464-410X.2011.10520.x. View

Seipel A, Delahunt B, Samaratunga H, Egevad L . Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features. Pathology. 2016; 48(5):398-405. DOI: 10.1016/j.pathol.2016.04.001. View

Tu S, Lopez A, Leibovici D, Bilen M, Evliyaoglu F, Aparicio A . Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer. 2009; 115(13):2872-80. DOI: 10.1002/cncr.24326. View

Seipel A, Wiklund F, Wiklund N, Egevad L . Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Arch. 2013; 462(4):429-36. DOI: 10.1007/s00428-013-1385-5. View

Knipper S, Preisser F, Mazzone E, Mistretta F, Tian Z, Briganti A . Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study. Clin Genitourin Cancer. 2019; 17(3):231-237.e2. DOI: 10.1016/j.clgc.2019.04.009. View

Marcus D, Goodman M, Jani A, Osunkoya A, Rossi P . A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis. 2012; 15(3):283-8. DOI: 10.1038/pcan.2012.4. View

Benedetto U, Head S, Angelini G, Blackstone E . Statistical primer: propensity score matching and its alternatives. Eur J Cardiothorac Surg. 2018; 53(6):1112-1117. DOI: 10.1093/ejcts/ezy167. View

10.

Wu Y, Chen S, Wang S, Li X, Cai H, Lin Y . Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study. Oncotarget. 2017; 8(17):29048-29055. PMC: 5438711. DOI: 10.18632/oncotarget.16070. View

11.

Bergamin S, Eade T, Kneebone A, Kench J, Sved P, Biset J . Ductal Carcinoma of the Prostate: An Uncommon Entity With Atypical Behaviour. Clin Oncol (R Coll Radiol). 2018; 31(2):108-114. DOI: 10.1016/j.clon.2018.10.011. View

12.

Fitzmaurice C, Allen C, Barber R, Barregard L, Bhutta Z, Brenner H . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2016; 3(4):524-548. PMC: 6103527. DOI: 10.1001/jamaoncol.2016.5688. View

13.

Igdem S, Spiegel D, Efstathiou J, Miller R, Poortmans P, Koca S . Prostatic duct adenocarcinoma: clinical characteristics, treatment options, and outcomes - a Rare Cancer Network study. Onkologie. 2010; 33(4):169-73. DOI: 10.1159/000288710. View

14.

Samaratunga H, Duffy D, Yaxley J, Delahunt B . Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Hum Pathol. 2009; 41(2):281-5. DOI: 10.1016/j.humpath.2009.08.010. View

15.

Packiam V, Patel S, Pariser J, Richards K, Weiner A, Paner G . Contemporary Population-Based Comparison of Localized Ductal Adenocarcinoma and High-Risk Acinar Adenocarcinoma of the Prostate. Urology. 2015; 86(4):777-82. DOI: 10.1016/j.urology.2015.07.009. View

16.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

17.

Orihuela E, Green J . Ductal prostate cancer: contemporary management and outcomes. Urol Oncol. 2008; 26(4):368-71. DOI: 10.1016/j.urolonc.2007.05.028. View

18.

Nakamura K, Terada N, Kobayashi T, Sugino Y, Yamasaki T, Matsui Y . [Clinical Characteristics of Prostate Ductal Adenocarcinoma in Kyoto University Hospital]. Hinyokika Kiyo. 2016; 61(12):487-91. View

19.

Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch M, De Santis M . EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2016; 71(4):618-629. DOI: 10.1016/j.eururo.2016.08.003. View

20.

Jeong S, Kekatpure A, Park J, Han M, Hwang H, Jeong H . Diverse Immunoprofile of Ductal Adenocarcinoma of the Prostate with an Emphasis on the Prognostic Factors. J Pathol Transl Med. 2017; 51(5):471-481. PMC: 5611530. DOI: 10.4132/jptm.2017.06.02. View